Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)-Reference-Cited by-同舟云学术

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

Published:2018-09-19 Issue:1 Volume:10 Page:
ISSN:1758-9193
Container-title:Alzheimer's Research & Therapy
language:en
Short-container-title:Alz Res Therapy

Author:

Salloway Stephen^ORCID,Honigberg Lee A.,Cho William,Ward Michael,Friesenhahn Michel,Brunstein Flavia,Quartino Angelica,Clayton David,Mortensen Deborah,Bittner Tobias,Ho Carole,Rabe Christina,Schauer Stephen P.,Wildsmith Kristin R.,Fuji Reina N.,Suliman Shehnaaz,Reiman Eric M.,Chen Kewei,Paul Robert

Funder

F. Hoffmann-La Roche

Publisher

Springer Science and Business Media LLC

Subject

Cognitive Neuroscience,Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1186/s13195-018-0424-5.pdf

Reference35 articles.

1. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698–712.

2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6.

3. Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron. 1991;6:487–98.